AntBO: Towards Real-World Automated Antibody Design with Combinatorial Bayesian Optimisation

• URL: http://arxiv.org/abs/2201.12570v1
• Date: Sat, 29 Jan 2022 12:03:04 GMT
• Title: AntBO: Towards Real-World Automated Antibody Design with Combinatorial Bayesian Optimisation
• Authors: Asif Khan, Alexander I. Cowen-Rivers, Derrick-Goh-Xin Deik, Antoine Grosnit, Kamil Dreczkowski, Philippe A. Robert, Victor Greiff, Rasul Tutunov, Dany Bou-Ammar, Jun Wang and Haitham Bou-Ammar
• Abstract summary: We present AntBO: a Combinatorial optimisation algorithm enabling efficient in silico design of the CDRH3 region. To benchmark AntBO, we use the Absolut! software suite as a black-box oracle because it can score the target specificity and affinity of designed antibodies in silico. In under 200 protein designs, AntBO can suggest antibody sequences that outperform the best binding sequence drawn from 6.9 million experimentally obtained CDRH3s.
• Score: 53.43922443725598
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: Antibodies are canonically Y-shaped multimeric proteins capable of highly specific molecular recognition. The CDRH3 region located at the tip of variable chains of an antibody dominates antigen-binding specificity. Therefore, it is a priority to design optimal antigen-specific CDRH3 regions to develop therapeutic antibodies to combat harmful pathogens. However, the combinatorial nature of CDRH3 sequence space makes it impossible to search for an optimal binding sequence exhaustively and efficiently, especially not experimentally. Here, we present AntBO: a Combinatorial Bayesian Optimisation framework enabling efficient in silico design of the CDRH3 region. Ideally, antibodies should bind to their target antigen and be free from any harmful outcomes. Therefore, we introduce the CDRH3 trust region that restricts the search to sequences with feasible developability scores. To benchmark AntBO, we use the Absolut! software suite as a black-box oracle because it can score the target specificity and affinity of designed antibodies in silico in an unconstrained fashion. The results across 188 antigens demonstrate the benefit of AntBO in designing CDRH3 regions with diverse biophysical properties. In under 200 protein designs, AntBO can suggest antibody sequences that outperform the best binding sequence drawn from 6.9 million experimentally obtained CDRH3s and a commonly used genetic algorithm baseline. Additionally, AntBO finds very-high affinity CDRH3 sequences in only 38 protein designs whilst requiring no domain knowledge. We conclude AntBO brings automated antibody design methods closer to what is practically viable for in vitro experimentation.

Related papers

• Relation-Aware Equivariant Graph Networks for Epitope-Unknown Antibody Design and Specificity Optimization [61.06622479173572]
  We propose a novel Relation-Aware Design (RAAD) framework, which models antigen-antibody interactions for co-designing sequences and structures of antigen-specific CDRs. Furthermore, we propose a new evaluation metric to better measure antibody specificity and develop a contrasting specificity-enhancing constraint to optimize the specificity of antibodies.
  arXiv  Detail & Related papers  (2024-12-14T03:00:44Z)
• Bayesian Optimization of Antibodies Informed by a Generative Model of Evolving Sequences [36.58091564004384]
  To build effective therapeutics, biologists iteratively mutate antibody sequences to improve binding and stability. Proposed mutations can be informed by previous measurements or by learning from large antibody databases to predict only typical antibodies. We introduce Clone-informed Bayesian Optimization (CloneBO), a Bayesian optimization procedure that efficiently optimize antibodies in the lab.
  arXiv  Detail & Related papers  (2024-12-10T18:57:48Z)
• Antigen-Specific Antibody Design via Direct Energy-based Preference Optimization [51.28231365213679]
  We tackle antigen-specific antibody sequence-structure co-design as an optimization problem towards specific preferences. We propose direct energy-based preference optimization to guide the generation of antibodies with both rational structures and considerable binding affinities to given antigens.
  arXiv  Detail & Related papers  (2024-03-25T09:41:49Z)
• xTrimoABFold: De novo Antibody Structure Prediction without MSA [77.47606749555686]
  We develop a novel model named xTrimoABFold to predict antibody structure from antibody sequence. The model was trained end-to-end on the antibody structures in PDB by minimizing the ensemble loss of domain-specific focal loss on CDR and the frame-aligned point loss.
  arXiv  Detail & Related papers  (2022-11-30T09:26:08Z)
• Incorporating Pre-training Paradigm for Antibody Sequence-Structure Co-design [134.65287929316673]
  Deep learning-based computational antibody design has attracted popular attention since it automatically mines the antibody patterns from data that could be complementary to human experiences. The computational methods heavily rely on high-quality antibody structure data, which is quite limited. Fortunately, there exists a large amount of sequence data of antibodies that can help model the CDR and alleviate the reliance on structure data.
  arXiv  Detail & Related papers  (2022-10-26T15:31:36Z)
• Reprogramming Pretrained Language Models for Antibody Sequence Infilling [72.13295049594585]
  Computational design of antibodies involves generating novel and diverse sequences, while maintaining structural consistency. Recent deep learning models have shown impressive results, however the limited number of known antibody sequence/structure pairs frequently leads to degraded performance. In our work we address this challenge by leveraging Model Reprogramming (MR), which repurposes pretrained models on a source language to adapt to the tasks that are in a different language and have scarce data.
  arXiv  Detail & Related papers  (2022-10-05T20:44:55Z)
• Iterative Refinement Graph Neural Network for Antibody Sequence-Structure Co-design [35.215029426177004]
  We propose a generative model to automatically design antibodies with enhanced binding specificity or neutralization capabilities. Our method achieves superior log-likelihood on the test set and outperforms previous baselines in designing antibodies capable of neutralizing the SARS-CoV-2 virus.
  arXiv  Detail & Related papers  (2021-10-09T18:23:32Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.